Sana Biotechnology (NASDAQ:SANA) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Sana Biotechnology (NASDAQ:SANA) issued its quarterly earnings results on Monday. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.01, FiscalAI reports.

Sana Biotechnology Stock Down 3.5%

Shares of Sana Biotechnology stock traded down $0.12 during trading hours on Wednesday, hitting $3.15. The company’s stock had a trading volume of 819,180 shares, compared to its average volume of 2,771,698. Sana Biotechnology has a 1-year low of $1.60 and a 1-year high of $6.55. The business has a fifty day moving average of $3.31 and a 200 day moving average of $4.00. The company has a market capitalization of $849.12 million, a PE ratio of -3.38 and a beta of 2.17.

Institutional Investors Weigh In On Sana Biotechnology

Large investors have recently made changes to their positions in the business. Jacobi Capital Management LLC acquired a new stake in shares of Sana Biotechnology in the fourth quarter worth $41,000. Mercer Global Advisors Inc. ADV purchased a new position in shares of Sana Biotechnology in the third quarter valued at $36,000. Cibc World Markets Corp purchased a new position in shares of Sana Biotechnology in the fourth quarter valued at $44,000. Commonwealth Equity Services LLC purchased a new position in shares of Sana Biotechnology in the fourth quarter valued at $45,000. Finally, Russell Investments Group Ltd. purchased a new position in shares of Sana Biotechnology in the third quarter valued at $39,000. Institutional investors and hedge funds own 88.23% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on SANA shares. Morgan Stanley reaffirmed an “overweight” rating and set a $12.00 price target on shares of Sana Biotechnology in a research report on Friday, March 13th. Zacks Research lowered shares of Sana Biotechnology from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 3rd. Weiss Ratings lowered shares of Sana Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 1st. HC Wainwright dropped their price target on shares of Sana Biotechnology from $9.00 to $7.00 and set a “buy” rating for the company in a research report on Wednesday, March 4th. Finally, Wall Street Zen raised shares of Sana Biotechnology from a “strong sell” rating to a “sell” rating in a research report on Saturday. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $9.50.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.